These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22785114)

  • 61. Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study.
    Soliman AR; Ismail E; Zamil S; Lotfy A
    Transplant Proc; 2009 Nov; 41(9):3639-41. PubMed ID: 19917358
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.
    McGovern AP; Jones S; van Vlymen J; Saggar AK; Sandford R; de Lusignan S
    BMC Nephrol; 2014 Nov; 15():182. PubMed ID: 25412767
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: impact on pain, hypertension, and renal function.
    Lee DI; Andreoni CR; Rehman J; Landman J; Ragab M; Yan Y; Chen C; Shindel A; Middleton W; Shalhav A; McDougall EM; Clayman RV
    J Endourol; 2003 Aug; 17(6):345-54. PubMed ID: 12965058
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
    Lantinga MA; D'Agnolo HM; Casteleijn NF; de Fijter JW; Meijer E; Messchendorp AL; Peters DJ; Salih M; Spithoven EM; Soonawala D; Visser FW; Wetzels JF; Zietse R; Drenth JP; Gansevoort RT;
    Drug Saf; 2017 Feb; 40(2):153-167. PubMed ID: 27995519
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
    Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
    Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
    Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.
    Peces R; Cuesta-López E; Peces C; Pérez-Dueñas V; Vega-Cabrera C; Selgas R
    Int Urol Nephrol; 2011 Jun; 43(2):565-9. PubMed ID: 20449653
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
    Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C
    Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
    Zafar I; Belibi FA; He Z; Edelstein CL
    Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Co-Inheritance of Autosomal Dominant Polycystic Kidney Disease and Naevoid Basal Cell Carcinoma Syndrome: Effects on Renal Progression.
    Martínez MF; Mazzuoccolo LD; Oddo EM; Iscoff PV; Muchnik C; Neumann HPH; Martin RS; Fraga AR; Azurmendi PJ
    Nephron; 2018; 140(4):282-288. PubMed ID: 30368514
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
    Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Risk factors for progression in ADPKD.
    Alam A
    Curr Opin Nephrol Hypertens; 2015 May; 24(3):290-4. PubMed ID: 25774748
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis.
    Gattone VH; Sinders RM; Hornberger TA; Robling AG
    Kidney Int; 2009 Jul; 76(2):178-82. PubMed ID: 19421190
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of the mammalian target of rapamycin (mTOR) in renal disease.
    Lieberthal W; Levine JS
    J Am Soc Nephrol; 2009 Dec; 20(12):2493-502. PubMed ID: 19875810
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics.
    Gitomer BY; Wang W; George D; Coleman E; Nowak KL; Struemph T; Cadnapaphornchai MA; Patel NU; Jovanovich A; Klawitter J; Farmer B; Ostrow A; You Z; Chonchol M
    Contemp Clin Trials; 2024 Feb; 137():107423. PubMed ID: 38151173
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Folate-conjugated rapamycin slows progression of polycystic kidney disease.
    Shillingford JM; Leamon CP; Vlahov IR; Weimbs T
    J Am Soc Nephrol; 2012 Oct; 23(10):1674-81. PubMed ID: 22859856
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Do mTOR inhibitors still have a future in ADPKD?
    Perico N; Remuzzi G
    Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768
    [No Abstract]   [Full Text] [Related]  

  • 80. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
    Myint TM; Rangan GK; Webster AC
    Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.